Vaxart (VXRT) Competitors $0.39 +0.00 (+0.03%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. RCKT, IMAB, ABEO, ALDX, CTNM, DSGN, ALT, FDMT, LRMR, and FHTXShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Rocket Pharmaceuticals (RCKT), I-Mab (IMAB), Abeona Therapeutics (ABEO), Aldeyra Therapeutics (ALDX), Contineum Therapeutics (CTNM), Design Therapeutics (DSGN), Altimmune (ALT), 4D Molecular Therapeutics (FDMT), Larimar Therapeutics (LRMR), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Its Competitors Rocket Pharmaceuticals I-Mab Abeona Therapeutics Aldeyra Therapeutics Contineum Therapeutics Design Therapeutics Altimmune 4D Molecular Therapeutics Larimar Therapeutics Foghorn Therapeutics Vaxart (NASDAQ:VXRT) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Which has stronger earnings & valuation, VXRT or RCKT? Vaxart has higher revenue and earnings than Rocket Pharmaceuticals. Vaxart is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M1.88-$66.95M-$0.25-1.56Rocket PharmaceuticalsN/AN/A-$258.75M-$2.51-1.26 Does the media prefer VXRT or RCKT? In the previous week, Vaxart had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 6 mentions for Vaxart and 4 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.66 beat Vaxart's score of 0.53 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of VXRT or RCKT? 18.0% of Vaxart shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 2.8% of Vaxart shares are held by company insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend VXRT or RCKT? Vaxart presently has a consensus target price of $2.00, suggesting a potential upside of 412.82%. Rocket Pharmaceuticals has a consensus target price of $16.73, suggesting a potential upside of 429.54%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Vaxart.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rocket Pharmaceuticals 1 Sell rating(s) 8 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.41 Which has more volatility and risk, VXRT or RCKT? Vaxart has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Is VXRT or RCKT more profitable? Rocket Pharmaceuticals has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Rocket Pharmaceuticals' return on equity of -65.11% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% Rocket Pharmaceuticals N/A -65.11%-55.99% SummaryRocket Pharmaceuticals beats Vaxart on 8 of the 15 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VXRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.29M$2.84B$5.78B$10.15BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-1.4423.5374.5925.92Price / Sales1.88534.82453.9085.92Price / CashN/A169.2537.0859.91Price / Book1.505.3712.156.29Net Income-$66.95M$32.95M$3.28B$270.85M7 Day Performance3.64%1.31%0.98%3.36%1 Month Performance0.78%8.31%7.20%6.41%1 Year Performance-57.05%0.29%63.06%28.26% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart2.0396 of 5 stars$0.39+0.0%$2.00+412.8%-58.5%$89.29M$47.40M-1.44120Gap DownRCKTRocket Pharmaceuticals4.7945 of 5 stars$3.26-0.6%$16.73+413.3%-82.8%$351.75MN/A-1.30240Positive NewsShort Interest ↑IMABI-Mab2.8108 of 5 stars$4.27-2.5%$7.00+63.9%+264.5%$348.69M$3.89M0.00380Analyst ForecastABEOAbeona Therapeutics4.2913 of 5 stars$6.70-2.8%$19.50+191.0%+20.8%$343.58M$3.50M9.5790Positive NewsALDXAldeyra Therapeutics2.1699 of 5 stars$5.70+2.5%$9.50+66.7%-10.2%$341.43MN/A-6.7110Positive NewsCTNMContineum Therapeutics2.6924 of 5 stars$12.13+5.5%$22.75+87.6%-34.0%$340.13M$50M-5.5131Short Interest ↑High Trading VolumeDSGNDesign Therapeutics0.2619 of 5 stars$5.82-9.8%N/A+14.2%$331.44MN/A-5.2040Positive NewsALTAltimmune2.5582 of 5 stars$3.71-1.9%$17.40+369.0%-48.5%$327.45M$20K-3.1450FDMT4D Molecular Therapeutics2.6717 of 5 stars$6.97-4.1%$30.40+336.2%-55.0%$325.50M$40K-1.97120News CoveragePositive NewsLRMRLarimar Therapeutics2.7689 of 5 stars$3.93-0.3%$18.43+368.9%-44.3%$325.33MN/A-2.5230FHTXFoghorn Therapeutics2.7633 of 5 stars$5.75-0.3%$10.67+85.5%-43.0%$325.05M$22.60M-4.83120Positive News Related Companies and Tools Related Companies Rocket Pharmaceuticals Competitors I-Mab Competitors Abeona Therapeutics Competitors Aldeyra Therapeutics Competitors Contineum Therapeutics Competitors Design Therapeutics Competitors Altimmune Competitors 4D Molecular Therapeutics Competitors Larimar Therapeutics Competitors Foghorn Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VXRT Stock Alerts